Navigation Links
PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022
Date:5/14/2013

Analysis, 2012 66Table 22: Summary of Alternative MS DMTs, 2012 67Table 23: Overall Unmet Needs – Current Level of Attainment 68Table 24: Clinical Unmet Needs – Gap Analysis, 2012 75Table 25: Multiple Sclerosis – Phase Pipeline, 2012 78Table 26: Comparison of Therapeutic Classes in Development for Multiple Sclerosis, 2012 80Table 27: Product Profile – BG-12 82Table 28: BG-12 SWOT Analysis, 2012 85Table 29: Product Profile – Lemtrada 87Table 30: Lemtrada SWOT Analysis, 2012 91Table 31: Product Profile – Laquinimod 93Table 32: Laquinimod SWOT Analysis, 2012 96Table 33: Product Profile – Daclizumab High-Yield Process 97Table 34: Daclizumab SWOT Analysis, 2012 101Table 35: Product Profile – Ocrelizumab 103Table 36: Ocrelizumab SWOT Analysis, 2012 106Table 37: Product Profile – Siponimod 107Table 38: Siponimod SWOT Analysis, 2012 110Table 39: Product Profile – NU-100 112Table 40: NU-100 SWOT Analysis, 2012 114Table 41: Product Profile – Masitinib 115Table 42: Masitinib SWOT Analysis, 2012 118Table 43: Product Profile – Tcelna 120Table 44: Tcelna SWOT Analysis, 2012 122Table 45: Sales Forecasts ($m) for Multiple Sclerosis in the United States, 2012-2022 125Table 46: Key Events Impacting Sales for Multiple Sclerosis the United States, 2012 127Table 47: Multiple Sclerosis Market in the United States – Drivers and Barriers, 2012 128Table 48: Key Launch Dates 147Table 49: Key Patent Expiries 147Table 50: Physicians Surveyed, By Country 155

List of Figures

Figure 1: Accrual of Disability in the Four Subtypes of Multiple Sclerosis 16Figure 2: Expanded Disability Status Scale (EDSS) 22Figure 3: Current Algorithm for the Treatment of MS with Disease-Modifying Therapies 26Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in Multiple Sclerosis, 2012–2022 79Figure 5: Sales for Multiple Sclerosis in the United
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022
2. PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022
3. PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022
4. In Relapsed/Refractory Multiple Myeloma, Thought Leaders Are Optimistic that the Combination of Carfilzomib, Lenalidomide and Dexamethasone Will Be the Most Efficacious Regimen
5. Hobart Group Holdings Marks 10th Anniversary With Multiple Milestones
6. Mapi Pharma Granted United States Patent Covering Glatiramer Depot for Multiple Sclerosis
7. For Pharma Companies, Launching Multiple Similar Products Can Be a "Good Problem" but Requires Smart Resourcing
8. Deploying an Effective Pay for Performance Bonus System that Works Across Multiple Industry Sectors
9. Aurigene Announces Transition of Multiple Programs to Clinical Development in its Collaboration Business
10. Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
11. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- Research and Markets has announced the ... Industry Report 2014" report to their offering. ... Global and Chinese Aseptic Packaging Industry Report is a ... the global Aseptic Packaging industry with a focus on ... overview of the industry including definitions, classifications, applications and ...
(Date:7/30/2014)... PITTSBURGH , July 30, 2014   ... Markets Groups Inc.: OTC Pink: UPZS), a Delaware ... a distribution agreement with Larasan Pharmaceutical Corporation ("Larasan"), a ... products.  According to the agreement, US-based Larasan will ... gourmet 6" frozen pizza through Larasan,s vast distribution ...
(Date:7/30/2014)... and PARIS , July 30, 2014 ... and Sanofi (EURONEXT: SAN and NYSE: SNY ... trials of alirocumab in people with hypercholesterolemia met their ... baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks ... investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type ...
Breaking Medicine Technology:Global and Chinese Aseptic Packaging Industry Report 2014 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8
... study shows 90-day statin drug claims filled through a mail ... supply from a retail pharmacy. The findings of the study ... management, will be presented at the Academy of Managed Care ... Minn. April 27-29. Waste occurs when patients stop ...
... /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... diagnostic ("IVD") company, today announced that it will report ... ("4Q FY2010") and the full fiscal year ended March ... June 2, 2011. The Company will also ...
Cached Medicine Technology:For Patients on Statins, Study Finds Filling 90 Day Supply Prescriptions through Mail Service Compared to Retail Pharmacy is Associated with Less Waste 2China Medical Technologies to Announce Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2011 on June 2, 2011 2
(Date:7/30/2014)... For patients with asthma, just believing an odor is ... at least 24 hours, a new study indicates. ... you think you smell," study author Cristina Jaen, a ... in a Monell news release. "Asthmatics often ... that an odor is harmful, our bodies react as ...
(Date:7/30/2014)... the vast majority of kids with autism have abnormal ... from children who have trouble processing sensory stimuli, researchers ... be overly sensitive to sound, sight and touch. They ... lack of concentration. Complicating matters, some kids with ... trouble tolerating loud noises, like a vacuum. Others can,t ...
(Date:7/30/2014)... were breastfed for three months or more as ... inflammation associated with cardiovascular and metabolic diseases, according ... University in St. Louis. , "This study shows ... children,s health decades later," said Molly W. Metzger, ... a co-author of the study with Thomas W. ...
(Date:7/30/2014)... July 30, 2014 On July 29, ... the Indian Institute of Public Health, Gandhinagar released a ... India, Volume II: The Way Forward .” The report ... on Policies and Practices to Improve Nutrition Security in ... Father of the Green Revolution" and chair of the ...
(Date:7/30/2014)... “Today, we have said ¡Basta! (enough) to ... promoted to our children and our families. The SWEET ... industry to put the health of people first and ... Delgado, President and CEO of the National Alliance for ... Tax (SWEET) Act by Congresswoman Rosa L. DeLauro. , ...
Breaking Medicine News(10 mins):Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 2Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 3Health News:Birthweight and breastfeeding have implications for children's health decades later 2Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 2Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 4Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act 2
... A study featured in the November issue of the ... simple questionnaire designed to identify patients at high risk of ... cases of cancer of the original 430 patients who qualified ... The study was conducted in primary care physician offices among ...
... ... with a compound that fights chronic liver disease Infections caused by Hepatitis C. Lloyd ... claim is incurable. The Blueberry Extract has a compound derived from blueberry leaves and ... , ...
... ... Targeted immunotherapy has been an attractive new therapeutic area for a ... cells without damaging surrounding normal tissue. New study results demonstrate high ... lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have ...
... ... its camera housings for underwater use, it turned to ZaGO Manufacturing Company for an answer. ... possibility of water leaking into the switch operating the camera. Vision Tech benefited from ... ...
... ... , ... -- Carmel Pharma, maker of the PhaSeal System for the safe handling of hazardous drugs, ... , , , , ,For safety and ease of use, the non-vented Secondary Set offers the ...
... November 2009 issue of the Journal of Thoracic Oncology ... and treatment may be attributed to health care system discrepancies. ... researchers studied the timing of lung cancer diagnosis and treatment ... patient population within two different hospital systems. David E. Gerber, ...
Cached Medicine News:Health News:Lloyd Wright's Alternative Medicine Marketing Only Blueberry Extract with 45% of Hepatitis C Inhibitor Proanthocyanidin 2Health News:Lloyd Wright's Alternative Medicine Marketing Only Blueberry Extract with 45% of Hepatitis C Inhibitor Proanthocyanidin 3Health News:Immunotherapy Demonstrates Long-Term Success in Treating Lymphoma 2Health News:Immunotherapy Demonstrates Long-Term Success in Treating Lymphoma 3Health News:Immunotherapy Demonstrates Long-Term Success in Treating Lymphoma 4Health News:ZaGO Manufacturing Company Seals the Deal -- Underwater 2Health News:Carmel Pharma Introduces PhaSeal Secondary Set (C60) 2
... Medication Delivery., ,Designed for adolescent ... incorporates an additional lumen and injection ... the cuff., ,SHERIDAN offers three ... CO2 monitoring, pressure monitoring or medication ...
... For Laryngotracheal Instillation of Topical Anesthetic, ... populations, this cuffed tube incorporates an ... spray application of topical anesthetic above ... offers three endotracheal tubes designs which ...
... ,Designed for neonatal and pediatric patient ... monitoring lumen within the wall of the ... Luer lock connector bonded to lumen line ... monitoring or syringe irrigation of medication., ...
SPIRAL-FLEX® Oral Precut Reinforced Tubes...
Medicine Products: